Obinutuzumab for refractory minimal change disease in obese patients: a case series
Frontiers in Medicine · 14.05.2026 · 13
DOI: 10.3389/fmed.2026.1842166 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 14.05.2026. Verfasst von Dandan Xue und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Research Fund Program of Affiliated Hospital of Jining Medical University.
Abstract (Originalsprache)
Minimal change disease (MCD) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, is effective in many cases, but up to 40% of patients show an insufficient or transient response. Obesity, a frequent comorbidity, is associated with chronic low-grade inflammation and B-cell dysfunction, which may contribute to suboptimal treatment outcomes. Obinutuzumab, a type II anti-CD20 antibody, induces more profound B-cell depletion than rituximab. We report two obese patients (BMI 32.10 and 42.45 kg/m 2 ) with biopsy-confirmed MCD who had an insufficient response to multiple immunosuppressive therapies, including rituximab. Patient 1 achieved complete remission with corticosteroids and tacrolimus; obinutuzumab (1 g) was added to enable rapid steroid withdrawal due to severe corticosteroid-induced acne. He remained in remission for >26 months after obinutuzumab, with CD19 + B-cell counts showing complete depletion (0 cells/μL), a rise to 103 cells/μL at 9 months (prompting a second dose). Patient 2 received obinutuzumab (1 g) for active disease after rituximab failure. He achieved complete remission but relapsed after immunosuppressant withdrawal. CD19 + B-cells had reconstituted to 75 cells/μL at relapse; a second obinutuzumab dose re-induced depletion (0 cells/μL) and remission, which was maintained at last follow-up. These observations suggest that obinutuzumab may induce and sustain remission in some obese patients with rituximab-insufficient MCD, and that obesity should be considered a potential modifier of treatment response in MCD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
- Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Förderung
- Talent Research Fund Program of Affiliated Hospital of Jining Medical University
Zitieren
APA
Xue, D., Ma, X., Li, X., Zhang, Y., & Xue, B. (2026). Obinutuzumab for refractory minimal change disease in obese patients: a case series. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1842166
Vancouver
Xue D, Ma X, Li X, Zhang Y, Xue B. Obinutuzumab for refractory minimal change disease in obese patients: a case series. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1842166
BibTeX
@article{Xue2026,
author = {Xue, Dandan and Ma, Xiaofen and Li, Xiang and Zhang, Yiming and Xue, Bing},
title = {Obinutuzumab for refractory minimal change disease in obese patients: a case series},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1842166}
}
EUVIMED